Lenvatinib

Lenvatinib

Chemical Structure

Overview

Lenvatinib, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. Acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases. The drug is also approved for hepatocellular carcinoma that cannot be removed surgically in patients who have not received cancer therapy by mouth or injection.

Key Features

  • Molecular Formula C21H19ClN4O4
  • Therapeutic Category Kinase Inhibitor
  • API Technology High Potent
  • Dose Form Oral

Use In

  • Differentiated Thyroid Cancer (DTC)

    Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

  • Renal Cell Carcinoma (RCC)

    First-line treatment, in combination with pembrolizumab, in adult patients with advanced renal cell carcinoma (RCC).

    Treatment of advanced renal cell carcinoma, in combination with everolimus, in adult patients who have previously tried ≥1 anti-angiogenic therapy.

  • Hepatocellular Carcinoma (HCC)

    First-line treatment of patients with unresectable hepatocellular carcinoma

  • Endometrial Carcinoma

    Treatment of advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), in combination with pembrolizumab, in patients who have experienced disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

Open Part Close Part IP BP USP EP IH
Available Under preparation
Send Inquiry